Copyright Reports & Markets. All rights reserved.

Encephalomyelitis - Pipeline Review, H1 2019

Buy now

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Encephalomyelitis - Overview

              Encephalomyelitis - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Encephalomyelitis - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Encephalomyelitis - Companies Involved in Therapeutics Development

                                      Astellas Pharma Inc

                                        Aurigene Discovery Technologies Ltd

                                          Biovista Inc

                                            Hemispherx Biopharma Inc

                                              ImmuneBiotech AB

                                                Inflazome Ltd

                                                  K-Pax Pharmaceuticals Inc

                                                    Philogen SpA

                                                      Encephalomyelitis - Drug Profiles

                                                        ASP-4058 - Drug Profile

                                                          Product Description

                                                            Mechanism Of Action

                                                              R&D Progress

                                                                CT-38 - Drug Profile

                                                                  Product Description

                                                                    Mechanism Of Action

                                                                      R&D Progress

                                                                        IB-003 - Drug Profile

                                                                          Product Description

                                                                            Mechanism Of Action

                                                                              R&D Progress

                                                                                JM-4 - Drug Profile

                                                                                  Product Description

                                                                                    Mechanism Of Action

                                                                                      R&D Progress

                                                                                        KPAX-002 - Drug Profile

                                                                                          Product Description

                                                                                            Mechanism Of Action

                                                                                              R&D Progress

                                                                                                MCC-950 - Drug Profile

                                                                                                  Product Description

                                                                                                    Mechanism Of Action

                                                                                                      R&D Progress

                                                                                                        nonathymulin - Drug Profile

                                                                                                          Product Description

                                                                                                            Mechanism Of Action

                                                                                                              R&D Progress

                                                                                                                ORNx-KI - Drug Profile

                                                                                                                  Product Description

                                                                                                                    Mechanism Of Action

                                                                                                                      R&D Progress

                                                                                                                        rintatolimod - Drug Profile

                                                                                                                          Product Description

                                                                                                                            Mechanism Of Action

                                                                                                                              R&D Progress

                                                                                                                                Small Molecule for Chronic Fatigue Syndrome - Drug Profile

                                                                                                                                  Product Description

                                                                                                                                    Mechanism Of Action

                                                                                                                                      R&D Progress

                                                                                                                                        Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile

                                                                                                                                          Product Description

                                                                                                                                            Mechanism Of Action

                                                                                                                                              R&D Progress

                                                                                                                                                Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile

                                                                                                                                                  Product Description

                                                                                                                                                    Mechanism Of Action

                                                                                                                                                      R&D Progress

                                                                                                                                                        tetravil - Drug Profile

                                                                                                                                                          Product Description

                                                                                                                                                            Mechanism Of Action

                                                                                                                                                              R&D Progress

                                                                                                                                                                WEHI-345 - Drug Profile

                                                                                                                                                                  Product Description

                                                                                                                                                                    Mechanism Of Action

                                                                                                                                                                      R&D Progress

                                                                                                                                                                        Encephalomyelitis - Dormant Projects

                                                                                                                                                                          Encephalomyelitis - Product Development Milestones

                                                                                                                                                                            Featured News & Press Releases

                                                                                                                                                                              Apr 24, 2018: New Hope for Patients with Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

                                                                                                                                                                                Appendix

                                                                                                                                                                                  Methodology

                                                                                                                                                                                    Coverage

                                                                                                                                                                                      Secondary Research

                                                                                                                                                                                        Primary Research

                                                                                                                                                                                          Expert Panel Validation

                                                                                                                                                                                            Contact Us

                                                                                                                                                                                              Disclaimer

                                                                                                                                                                                              Encephalomyelitis - Pipeline Review, H1 2019

                                                                                                                                                                                              Summary

                                                                                                                                                                                              Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H1 2019, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

                                                                                                                                                                                              Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.

                                                                                                                                                                                              Report Highlights

                                                                                                                                                                                              Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                                                                              The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

                                                                                                                                                                                              Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                                                                              Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                              Scope

                                                                                                                                                                                              - The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
                                                                                                                                                                                              - The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                                                                              - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                                                                              - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                                                                              - The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
                                                                                                                                                                                              - The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                                                                              - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                                                                              - The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)

                                                                                                                                                                                              Reasons to buy

                                                                                                                                                                                              - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                                                                              - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                                                                              - Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
                                                                                                                                                                                              - Classify potential new clients or partners in the target demographic.
                                                                                                                                                                                              - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                                                                              - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                                                                              - Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
                                                                                                                                                                                              - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                                                                              - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

                                                                                                                                                                                              Buy now